Compare LKFN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | VCEL |
|---|---|---|
| Founded | 1872 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2009 | 1996 |
| Metric | LKFN | VCEL |
|---|---|---|
| Price | $57.25 | $32.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $67.00 | $57.75 |
| AVG Volume (30 Days) | 143.0K | ★ 577.3K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | 10.47 | ★ 60.00 |
| EPS | ★ 1.04 | N/A |
| Revenue | $985,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $15.50 | $19.40 |
| Revenue Next Year | $5.51 | $18.24 |
| P/E Ratio | $55.86 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $54.36 | $28.95 |
| 52 Week High | $69.38 | $45.97 |
| Indicator | LKFN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 43.49 |
| Support Level | $55.37 | $30.41 |
| Resistance Level | $61.80 | $34.77 |
| Average True Range (ATR) | 1.70 | 2.05 |
| MACD | -0.56 | -0.35 |
| Stochastic Oscillator | 1.96 | 12.24 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.